| SC 13G/A | 2020-02-11 | UBS Group AG | Paratek Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2020-02-05 | BlackRock Inc. | Paratek Pharmaceuticals, Inc. | 2,323,912 | 7.0% | EDGAR |
| SC 13G/A | 2019-12-09 | BAUPOST GROUP LLC/MA | Paratek Pharmaceuticals, Inc. | 1,552,286 | 4.7% | EDGAR |
| SC 13G | 2019-02-15 | UBS Group AG | Paratek Pharmaceuticals, Inc. | 2,119,933 | 6.6% | EDGAR |
| SC 13G/A | 2019-02-14 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | Paratek Pharmaceuticals, Inc. | 2,799,479 | 8.0% | EDGAR |
| SC 13G/A | 2019-02-14 | ARMISTICE CAPITAL, LLC | Paratek Pharmaceuticals, Inc. | 1,968,000 | 6.1% | EDGAR |
| SC 13G | 2019-02-14 | HIGHLAND CAPITAL MANAGEMENT LP | Paratek Pharmaceuticals, Inc. | 2,204,865 | 6.9% | EDGAR |
| SC 13G/A | 2019-02-06 | BlackRock Inc. | Paratek Pharmaceuticals, Inc. | 2,676,432 | 8.3% | EDGAR |
| SC 13G | 2018-11-13 | ARMISTICE CAPITAL, LLC | Paratek Pharmaceuticals, Inc. | 1,672,000 | 5.2% | EDGAR |
| SC 13G | 2018-04-30 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | Paratek Pharmaceuticals, Inc. | 2,201,258 | 6.5% | EDGAR |
| SC 13G/A | 2018-02-14 | Abingworth LLP | Paratek Pharmaceuticals, Inc. | 1,041,131 | 3.7% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Paratek Pharmaceuticals, Inc. | 1,166,292 | 4.8% | EDGAR |
| SC 13G/A | 2018-02-13 | BAUPOST GROUP LLC/MA | Paratek Pharmaceuticals, Inc. | 2,394,498 | 8.6% | EDGAR |
| SC 13G/A | 2018-01-29 | BlackRock Inc. | Paratek Pharmaceuticals, Inc. | 1,903,651 | 6.8% | EDGAR |
| SC 13G/A | 2017-03-22 | HBM Healthcare Investments (Cayman) Ltd. | Paratek Pharmaceuticals, Inc. | 1,203,202 | 5.0% | EDGAR |
| SC 13D/A | 2017-03-10 | Omega Fund III, L.P. | Paratek Pharmaceuticals, Inc. | 1,191,448 | 5.3% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Paratek Pharmaceuticals, Inc. | 2,115,592 | 9.7% | EDGAR |
| SC 13G/A | 2017-02-14 | BAUPOST GROUP LLC/MA | Paratek Pharmaceuticals, Inc. | 2,044,498 | 9.0% | EDGAR |
| SC 13G | 2017-02-14 | HBM Healthcare Investments (Cayman) Ltd. | Paratek Pharmaceuticals, Inc. | 1,353,202 | 6.0% | EDGAR |
| SC 13G | 2017-01-30 | BlackRock Inc. | Paratek Pharmaceuticals, Inc. | 1,300,022 | 5.7% | EDGAR |